Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new strategic partnership between Fiocruz and The Global Health Network will amplify the impact of Fiocruz’s health research and capacity development initiatives by promoting research capacity building across Portuguese-speaking countries, and enabling research findings from the Zika outbreak to benefit public health worldwide.

Signing of the agreement between The Global Health Network and Fiocruz

Fiocruz, one of the world’s leading public health institutions and Brazil’s institute for health science and technology, has signed an agreement with The Global Health Network at the University of Oxford to enable evidence generated from research to drive improvements in global health in the most resource-poor and hard to reach areas of the globe.

This new partnership will:

  • Establish a knowledge sharing hub for Fiocruz, embedded within The Global Health Network. This hub will enhance the visibility of Fiocruz’s research and capacity development activities on this global platform. It will both connect existing partners and promote new partnerships, inviting the rest of the world to learn from and benefit from their advances. 
  • Promote research capacity building across Portuguese-speaking countries. With an initial focus on Angola, followed by Mozambique, Fiocruz and The Global Health Network will collaborate with local research organisations to promote access to training, support, tools and resources for local health works – all in Portuguese. This aims to overcome language as a barrier to conducting research, giving health workers the skills and training to build their career through research experience.
  • Share research findings and recommendations from the Zika outbreak. A knowledge sharing hub will consolidate and communicate findings from the three Zika research consortia to health workers, research teams and, most importantly, the families impacted by this devastating outbreak. It will provide a powerful mechanism for sharing the findings and helping these results get back to the community, local health delivery teams and into practice to make a lasting impact. Through sharing recommendations arising from research during the outbreak, the results can be used for public health benefit and, over time, become an integral part of vector control activities. This is an important outcome for ZikaPLAN and ZIKAction*, and for ZIKAlliance an opportunity to contribute by sharing information that can be useful for feeding the platform.

Fiocruz has a long history of embedding health research into health systems and building research capacity through equipping health workers with the skills to put research results into practice and generate evidence, with outcomes that improve the lives of their communities. The Global Health Network brings its extensive experience in knowledge sharing and communities of practice to amplify the impact of Fiocruz’s work on a global scale.

A shared ethos between Fiocruz and The Global Health Network underpins this partnership: firstly, that public health can be improved through research and, secondly, in which the advances from each programme enriches the others. By building capacity for research across the globe, evidence can be generated where such data is missing, across diseases, geographies and communities, and the impacts of this research can be accelerated when methods, best practice and experience are shared.

About The Global Health Network

More, better and faster research is critical to solving the world’s biggest health challenges. The Global Health Network is sharing knowledge, methods and tools between disease areas, regions and organisations to amplify evidence generation. Research teams and professionals are being trained and supported to lead and undertake health research in the world’s most challenging settings. This is achieved by applying the best digital technology and harnessing the sharing phenomena, working virtually and on the ground to enable the capture of life-saving data.

About Fiocruz

Fiocruz is the most prominent Institution of Science and Technology in Health in Latin America, whose mission is to produce, disseminate and share knowledge and technologies, aiming at strengthening and consolidating the Unified Health System and the promotion of health and quality of life for the population

Funding

Eu flag *This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No.s 734584, 734857.

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

UK National Health Service begins rollout of Oxford coronavirus vaccine

@Oxford General

The first patients are being vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, at the Oxford University NHS Hospitals Trust. The Oxford AstraZeneca vaccinations will be delivered at a small number of hospitals for the first few days for surveillance purposes, as is standard practice, before the bulk of supplies are sent to hundreds of GP-led services later in the week.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

Susie Dunachie awarded flagship NIHR career development award

@Oxford Awards & Appointments

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.